Search

Copyright of Coal Science & Technology (0253-2336) is the property of Coal Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To analyze the efficacy and safety of apatinib in extensive-stage small cell lung cancer (ES-SCLC), and to provide a reference for the clinical treatment of ES SCLC. Methods Twenty-two patients with advanced ES-SCLC admitted to the hospital from September 2015 to February 2018 were selected as the research subjects. 12 first-line patients received apatinib combined with chemotherapy and apatinib single-agent maintenance treatment after chemotherapy. 10 patients and above were treated with apatinib monotherapy, 21 days of treatment was one cycle, and the full analysis set included all patients who had been treated for at least one cycle. Observation and analysis of 22 patients' medication status, efficacy, death, and occurrence of adverse drug reactions. The primary endpoint of treatment is the objective response rate, and the secondary endpoints are progression-free survival (PFS), disease control rate, overall survival (OS) and treatment safety. Results The median OS of 22 patients was 11.1 months, and the median PFS was 5.6 months. Among the 22 patients, 1 case was complete remission, 9 cases were partial remission, 8 cases were stable, and 4 cases progressed: occurred in 22 patients. There were 14 cases (63.6%) of various types of adverse reactions, 5 cases (22.7%) of grade ≥||. The main types of adverse reactions were hand-foot skin reactions, hypertension, and proteinuria. The common adverse reactions of grade ≥ were hypertension and hand-foot skin. reaction. Conclusion Choosing apatinib as the first-line and maintenance treatment of ES-SCLC has good safety, obvious overall curative effect, and has the value of promotion and application. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Modern Medicine & Health is the property of Journal of Modern Medicine & Health and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Targeted at the particle migration process, energy source and transmission of CH4 during its desorption process, the vitrain and durain in No. 4 Mine of Dafosi are stripped to conduct a series of contrast experiments concerning industrial analysis, coal petrographical analysis, liquid nitrogen adsorption, mercury injection experiments, wetting testing, adsorption and desorption, and then the adsorption heats are calculated. It is discovered that (1) In terms of mass transfer function, coal pores are classified into semi-open pores and interconnected pores. With large adsorbing capacity, vitrain mainly has semi-open pores, and durain mainly has interconnected ones. (2) Depressurization turbulence leads to water vaporization. Heat release from the adsorption of H2O leads to the desorption of CH4. The nature of depressurization desorption is competitive adsorption, manifesting as replacement desorption. (3) The mass transfer process of CBM is a cavitation process of CH4 gas nucleus with low solubility. The water adsorption of coal, equilibrium water experiments and the results of CT scanning all basically verify the understanding of the mass transfer process of CBM production. The research results supplement the issue of energy source of adsorption. [ABSTRACT FROM AUTHOR]